Abstract: The present invention provides a spray-applied polyurethane insulation material for tunnels in cold regions, its application, and its construction method. The spray-applied polyurethane insulation material for tunnels in cold regions is composed of raw materials with a mass ratio of 0.8-1.2 of material A and material B. By mass parts, material A includes 90-100 parts of polyether polyol, 90-100 parts of polyester polyol, 5-10 parts of chain extender, 1-4 parts of catalyst, 10-20 parts of flame retardant, 0.5-3 parts of water, and 1-3 parts of surfactant. The B component is diphenylmethane diisocyanate. The flame retardant is composed of flame retardant A and flame retardant B in a mass ratio of 10:1-2.5. The spray-applied polyurethane insulation material of the present invention is used to construct tunnel structures in cold regions, providing good flame retardant and insulation effects.

Abstract: The present invention provides a spray-applied polyurethane insulation material for tunnels in cold regions, its application, and its construction method. The spray-applied polyurethane insulation material for tunnels in cold regions is composed of raw materials with a mass ratio of 0.8-1.2 of material A and material B. By mass parts, material A includes 90-100 parts of polyether polyol, 90-100 parts of polyester polyol, 5-10 parts of chain extender, 1-4 parts of catalyst, 10-20 parts of flame retardant, 0.5-3 parts of water, and 1-3 parts of surfactant. The B component is diphenylmethane diisocyanate. The flame retardant is composed of flame retardant A and flame retardant B in a mass ratio of 10:1-2.5. The spray-applied polyurethane insulation material of the present invention is used to construct tunnel structures in cold regions, providing good flame retardant and insulation effects.

Abstract: A system that transdermally delivers a drug to a patient can be used to reduce suffering from acute/chronical musculoskeletal pain. The system includes a backing layer, an adhesive layer, a topical applicator, a suitable quantity of drug, and a quantity of topical carrier. The topical applicator is connected across and against the backing layer by the adhesive layer. The suitable quantity of drug and the quantity of topical carrier are homogenously mixed together as a topical medication, which is retained and dispensed from the topical applicator. The topical applicator includes a flat applicator body, a plurality of blunted spikes, and a containment rim. The flat applicator body is the structural base of the topical applicator. The containment rim is used to perimetrically confine the topical medication. The blunted spikes are used to increase the surface area of the topical applicator in order to improve its retention of the topical medication.

Abstract: A system that transdermally delivers a drug to a patent can be used to reduce suffering from acute/chronical musculoskeletal pain. The system includes a backing layer, an adhesive layer, a topical applicator, a suitable quantity of drug, and a quantity of topical carrier. The topical applicator is connected across and against the backing layer by the adhesive layer. The suitable quantity of drug and the quantity of topical carrier are homogenously mixed together as a topical medication, which is retained and dispensed from the topical applicator. The topical applicator includes a flat applicator body, a plurality of blunted spikes, and a containment rim. The flat applicator body is the structural base of the topical applicator. The containment rim is used to perimetrically confine the topical medication. The blunted spikes are used to increase the surface area of the topical applicator in order to improve its retention of the topical medication.

Abstract: This disclosure relates to the field of electrochemistry, and in particular, to a positive electrode material, an electrochemical energy storage apparatus and a vehicle. The positive electrode material of this disclosure includes a substrate, with a formula of the substrate being LixNiyCOzMkMepOrAm, where 0.95?x?1.05, 0.50?y?0.95, 0?z?0.2, 0?k?0.4, 0?p?0.05, 1?r?2, 0?m?2, m+r?2; a coating layer is disposed on the substrate, where the coating layer includes a coating element; and absorbance of nickel leachate per unit mass of the positive electrode material w?0.7.

Abstract: This disclosure relates to the field of electrochemistry, and in particular, to a positive electrode material. The positive electrode material of this disclosure includes a substrate, with a formula of the substrate being LixNiyCozMkMepOrAm, where 0.95?x?1.05, 0.50?y?0.95, 0?z?0.2, 0?k?0.4, 0?p?0.05, 1?r?2, 0?m?2, m+r?2; a coating layer is disposed on the subs hate, where the coating layer includes a coating element; and absorbance of nickel leachate per unit mass of the positive electrode material w?0.7.

Abstract: This disclosure relates to the field of electrochemistry, and in particular, to a positive electrode material. The positive electrode material of this disclosure includes a substrate, with a formula of the substrate being LixNiyCozMkMepOrAm, where 0.95?x?1.05, 0.50?y?0.95, 0?z?0.2, 0?k?0.4, 0?p?0.05, 1?r?2, 0?m?2, m+r?2; a coating layer is disposed on the subs hate, where the coating layer includes a coating element; and absorbance of nickel leachate per unit mass of the positive electrode material w?0.7.

Abstract: The present invention is directed to novel 2-amino-3,4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of ?-secretase, also known as ?-site cleaving enzyme and BACE.

Abstract: The present invention is directed to 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of ?-secretase, also known as ?-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.

Abstract: The present invention is directed to novel 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD), mild cognitive impairment, senility and/or dementia. The compounds of the present invention are inhibitors of ?-secretase, also known as ?-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2.

Abstract: The present invention is directed to novel 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD), mild cognitive impairment, senility and/or dementia. The compounds of the present invention are inhibitors of ?-secretase, also known as ?-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2.

Abstract: The present invention is directed to novel 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of ?-secretase, also known as ?-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.

Abstract: The present invention is directed to 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of ?-secretase, also known as ?-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.

Abstract: The present invention is directed to novel 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of ?-secretase, also known as ?-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.

Abstract: The present invention is directed to novel 2-amino-3,4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of ?-secretase, also known as ?-site cleaving enzyme and BACE.

Abstract: Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives of the general formula wherein all variables are as described herein, useful in the treatment of disorders, such as depression, dementia, schizophrenia, bipolar disorders, anxiety, emesis, acute or neuropathic pain, itching, migraine and movement disorders.

Abstract: Amino pyrazole derivatives of the formula: which are ligands for the neuropeptide Y, subtype 5 receptor and pharmaceutical compositions containing an amino pyrazole derivative as the active ingredient are described. The amino pyrazole derivatives are useful in the treatment of disorders and diseases associated with the NPY receptor subtype Y5.

Abstract: Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives of the general formula 1

Abstract: Amino pyrazole derivatives of the formula: 1